Ratings Shockwave Medical, Inc.

Equities

SWAV

US82489T1043

Real-time Estimate Cboe BZX Other stock markets 20:05:27 01/05/2024 BST			5-day change	1st Jan Change
330.1 ^USD	-0.02%		+0.51%	+73.47%

04-11	Health Care Slips on Risk Bias -- Health Care Roundup	DJ
04-09	CL King Downgrades ShockWave Medical to Neutral From Buy, Cuts Price Target to $335 From $368	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 68.32 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
SHOCKWAVE MEDICAL, INC.	+73.47%	12.38B	B-
PENUMBRA, INC.	-17.33%	7.61B	C+
MASIMO CORPORATION	+15.14%	7.11B	C-
GETINGE AB	+4.77%	5.83B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+11.77%	5.35B	D+
APT MEDICAL INC.	+29.65%	4.63B	-
ASAHI INTECC CO., LTD.	-19.09%	4.02B	B-
INARI MEDICAL, INC.	-34.13%	2.16B	C
SKAN GROUP AG	+1.24%	2.01B	-
SHENZHEN YHLO BIOTECH CO., LTD.	+4.85%	1.88B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes